Docket No.: UMY-034

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Mario Stevenson et al.

Application No.: 10/722,689

Confirmation No.: 3913

Filed: November 24, 2003

Art Unit: 1635

For:

MODULATION OF HIV REPLICATION BY

RNA INTERFERENCE

Examiner: Richard A. Schnizer

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)

Dear Sir:

In accordance with 37 CFR 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

Application No.: 10/722,689 Docket No.: UMY-034

In accordance with 37 CFR §1.97(c)(2) and §1.17(p), please charge the \$180.00 submission fee to our Deposit Order Account No. 12-0080. Please charge any necessary additional fees or credit any overpayments to our Deposit Order Account No. 12-0080.

Dated: July 16, 2007

DJM/JHV/jcb

Respectfully submitted,

Debra J. Milasincic, Esq.

Registration No.: 46,931

James H. Velema

Registration No.: 56,130

LAHIVE & COCKFIELD, LLP


One Post Office Square

Boston, Massachusetts 02109-2127

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicant



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	

	Complete if Known				
Application Number 10/722,689-Conf. #3913					
Filing Date	November 24, 2003				
First Named Inventor	Mario STEVENSON				
Art Unit	1635				
Examiner Name	Richard A. Schnizer				
Attorney Docket Number	UMY-034				

			U.S. PA	TENT DOCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	A1*	US-6,426,073	07-30-2002	Alizon et al.	
	A2*	US-20020086356-A1	07-04-2002	Tuschl et al.	
	A3*	US-20030055020-A1	03-20-2003	Fire et al.	
	A4*	US-20030068821	04-10-2003	Lois-Caballe et al.	
	A5*	US-20030101472-A1	05-29-2003	Baltimore et al.	
	A6*	US-20030124513-A1	07-03-2003	McSwiggen	
	A7*	US-20030175950-A1	09-18-2003	McSwiggen	
	A8*	US-20040192629-A1	09-30-2004	Xu et al.	
	A9*	US-20040229266-A1	11-18-2004	Tuschl et al.	
	A10*	US-20040259248-A1	12-23-2004	Tuschl et al.	
	A11*	US-20050026278-A1	02-03-2005	Tuschl et al.	
	A12*	US-20050181382-A1	08-18-2005	Zamore et al.	
	A13*	US-20050191618-A1	09-01-2005	McSwiggen et al.	
	A14*	US-20050234007-A1	10-20-2005	Tuschl et al.	
	A15*	US-20070003960-A1	01-04-2007	Tuschl et al.	
	A16*	US-20070003963-A1	01-04-2007	Tuschl et al.	
	A17*	US-7,195,916-A1	03-27-2007	Qin et al.	
	A18*	US-20030051263-A1	03-13-2003	Fire et al.	
	A19*	US-20030056235-A1	03-20-2003	Fire et al.	
	A20*	US-20030101471-A1	05-29-2003	Baltimore et al.	
	A21*	US-20030108923-A1	06-12-2003	Tuschl et al.	
	A22*	US-20030157691-A1	08-21-2003	Qin et al.	
	A23*	US-20040006035-A1	01-08-2004	Macejak et al.	
	A24*	US-20040203145-A1		Zamore et al.	
		US-20040259247-A1	12-23-2004	Tuschl et al.	
	A26*	US-20050020525-A1	01-27-2005	McSwiggen et al.	
	A27*	US-20050037988-A1	02-17-2005	Zamore et al.	
	A28*	US-20050186586-A1	08-25-2005	Zamore et al.	
	A29*	US-20050234006-A1	10-20-2005	Tuschl et al.	
		US-20060009402-A1		Zamore et al.	
		US-20070003962-A1		Tuschl et al.	

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T⁵				
	B1	WO-02/44321-A2	06-06-2002	Maxplanck-Gesellschaft						
	B2	WO-2004/014933-A1	02-19-2004	University of Massachusetts		П				
	B3	WO-2004/111191-A2	12-23-2004	University of Massachusetts						
	B4	WO-2004/042027-A2	05-21-2004	University of Massachusetts						

Examiner		Date	·	
Signature		Considered		

Sub	stitute for form 1449/PTO			Complete if Known		
				Application Number	10/722,689-Conf. #3913	
l IN	IFORMATION	N DI	SCLOSURE	Filing Date	November 24, 2003	
l s	STATEMENT BY APPLICANT			First Named Inventor Mario STEVENSON		
				Art Unit	1635	
	(Use as many sh	eets as	necessary)	Examiner Name	Richard A. Schnizer	
Sheet	2	of	4	Attorney Docket Number	UMY-034	

B5	WO-01/75164-A2	10-11-2001	Whitehead Institute for Biomedical Research	
B6	WO-2005/001043-A2	01-06-2005	University of Massachusetts	
B7	WO-03/006477-A1	01-23-2003	University of Massachusetts	
B8	WO-03/022052-A1	03-20-2003	California Institute of Technology	
В9	WO-2003/070193-A2	08-28-2003	Sirna Therapeutics, Inc.	
B10	WO-03/022228-A2	03-20-2003	California Institute of Technology	
B11	WO-03/102131-A2	12-11-2003	Sirna Therapeutics, Inc.	1 1 1
B12	WO-03/022040-A2	03-20-2003	California Institute of Technology	
B13	WO-02/097114-A2	12-05-2002	Ribozyme Pharmaceuticals, Inc.	The state of the s
B14	WO-2005/019453-A2	03-03-2005	Sirna Therapeutics, Inc.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Arteaga, Jose et al., "Choosing CCR5 or Rev siRNA in HIV-1," Nature, Vol. 21:230-31 (2003)	
	C2	Bernstein, Emily et al., "Role for a bidentate ribonuclease in the initiation step of RNA interference," <i>Nature</i> , Vol. 409:363-366 (2001)	
	C3	Billy, Eric et al., "Specific interference with gene expression induced by long, double-stranded RNA in mouse embryonal teratocarcinoma cell lines," <i>PNAS</i> , Vol. 98(25):14428-14433 (2001)	
	C4	Bitko, Vira et al., "An Endoplasmic Reticulum-Specific Stress-Activated Caspase (Caspase-12) is Implicated in the Apoptosis of A549 Epithelial Cells by Respiratory Syncytial Virus," <i>Journal of Cellular Biology</i> , Vol. 80: 441-454 (2001)	5
	C5	Bitko, Vira et al., "Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA," <i>BMC Microbiology</i> , Vol. 1(34): 1-11 (2001)	
ļ	C6	Bowerman, Bruce et al., "A nucleoprotein complex mediates the integration of retroviral DNA," Genes & Development, Vol. 3:469-478 (1989)	
	C7	Brichacek, Beda et al., "Quantitative Competitive RNA PCR for Quantitation of Virion-Associated HIV-1 RNA," <i>Methods</i> , Vol. 12:294-299 (1997)	
	C8	Caplen, Natasha et al., "dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference," Gene, Vol. 252:95-105 (2000)	
	C9	Caplen, Natasha et al., "Specific inhibition of gene expression by small double stranded RNAs	

Examiner	Date	
Signature	Considered	

Sub	stitute for form 1449/PTO				Complete if Known	
				Application Number	10/722,689-Conf. #3913	
10	NFORMATION		SCLOSURE	Filing Date	November 24, 2003	
S	TATEMENT E	BY A	APPLICANT	First Named Inventor	Mario STEVENSON	
				Art Unit	1635	
	(Use as many she	ets as	necessary)	Examiner Name	Richard A. Schnizer	
Sheet	3	of	4	Attorney Docket Number	UMY-034	

	in invertebrate and vertebrate systems," PNAS, Vol. 98(17):9742-9747 (2001)
C10	Coburn, Glen et al., "Potent and Specific Inhibition of Human Immunodeficiency Virus Type 1 Replication by RNA Interference," <i>Journal of Virology</i> , Vol. 76(18):9225-9231 (2002)
C11	Dornburg, Ralph et al., "HIV-1 Gene Therapy: Promise for the Future," <i>Advances in Pharmacology</i> , Vol. 49:229-261 (2000)
C12	
C13	
C14	
C15	Fire, Andrew et al., "Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans," Nature, Vol. 391:806-811 (1998)
C16	Hammond, Scott et al., "An RNA-directed nuclease mediates post-transciptional gene silencing in Drosophila cells," <i>Nature</i> , Vol. 404:293-296 (2000)
C17	& Development, Vol. 12:225-232 (2002)
C18	Ketting, René et al., "mut-7 of C. elegans, Required for Transposon Silencing and RNA Interference, Is a Homolog of Werner Syndrome Helicase and RNaseD," <i>Cell</i> , Vol. 99:133-141 (1999)
C19	Kimpton, Jaculyn et al., "Detection of Replication-Competent and Pseudotyped Human Immunodeficiency Virus with a Sensitive Cell Line on the Basis of Activation of an Integrated \(\beta\)-Galactosidase Gene," Journal of Virology, Vol. 66(4):2232-2239 (1992)
C20	
C21	
C22	Nykänen, Antti et al., "ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway," Cell, Vol. 107:309-321 (2001)
C23	
C24	Sharkey, Mark et al., "Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy," <i>Nature Medicine</i> , Vol. 6(1):76-81 (2000)
C25	Sharp, J.G. et al., "Oligonucleotide Enhanced Cytotoxicity of Idarubicin for Lymphoma Cells," Leukemia and Lymphoma, Vol. 42:417-427 (2001)
C26	
C27	Tabara, Hiroaki et al., "The <i>rde-1</i> Gene, RNA Interference and Transpoon Silencing in <i>C. elegans</i> ," <i>Cell</i> , Vol. 99:123-132 (1999)
C28	cultured cells using firefly luciferase gene as target," FEBS Letters, Vol. 479:79-82 (2000)
C29	

Examiner	Date	
Signature	Considered	

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/722,689-Conf. #3913
11	VFORMATIO	N DI	SCLOSURE	Filing Date	November 24, 2003
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Mario STEVENSON
(Use as many sheets as necessary)				Art Unit	1635
				Examiner Name	Richard A. Schnizer
Sheet	4	of	4	Attorney Docket Number	UMY-034

C30	Welker, Reinhold et al., "Virion Incorporation of Human Immunodeficiency Cirus Type 1 Nef Is Mediated by a Bipartite Membrane-Targeting Signal: Analysis of Its Role in Enhancement of Viral Infectivity," <i>Journal of Virology</i> , Vol. 72(11):8833-8840 (1998)	
C31	Wesley, S. Varsha et al., "Construct design for efficient, effective and high-throughput gene silencing in plants," <i>The Plant Journal</i> , Vol. 27(6):581-590 (2001)	
C32	Yang, Shicheng et al., "Specific Double-Stranded RNA Interference in Undifferentiated Mouse Embryonic Stem Cells," <i>Molecular and Cellular Biology</i> , Vol. 21(22):7807-7816 (2001)	
C33	Zamore, Phillip et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," Cell, Vol. 101:25-33 (2000)	
C34	International Search Report for Application No. PCT/US03/37860 dated 7/21/2005	
C35	Written Opinion for Application No. PCT/US03/37860 dated 5/31/2007	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

¹Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.